4
Changes in Ownership
Vera Therapeutics, Inc. Filed Acc 0001415889-25-001242
PRESIDENT AND CEO sold 17,500 shares at an average $41.74 ($730,535)
- PRESIDENT AND CEO acquired 17,500 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Fordyce Marshall · PRESIDENT AND CEO
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-01-08 | Exercise or conversion : show line 1 in the form 10b5-1 | +9,975 | $2.90 | $28,896 | 153,578 | D |
| 2025-01-08 | Sale : show line 2 in the form 10b5-1 | −9,975 | $41.53 | $414,297 | 143,603 | D |
| 2025-01-08 | Exercise or conversion : show line 3 in the form 10b5-1 | +5,650 | $2.90 | $16,367 | 149,253 | D |
| 2025-01-08 | Sale : show line 4 in the form 10b5-1 | −5,650 | $42.03 | $237,489 | 143,603 | D |
| 2025-01-08 | Exercise or conversion : show line 5 in the form 10b5-1 | +1,875 | $2.90 | $5,432 | 145,478 | D |
| 2025-01-08 | Sale : show line 6 in the form 10b5-1 | −1,875 | $42.00 | $78,750 | 143,603 | D |
| Open-market sales · 17,500 sh · avg $41.74 · $730,535 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2025-01-08 | Exercise or conversion : show line 7 in the form 10b5-1 Stock Option (Right to Buy) | −15,625 | 610,926 | D |
| 2025-01-08 | Exercise or conversion : show line 8 in the form 10b5-1 Stock Option (Right to Buy) | −1,875 | 609,051 | D |
Loading xslF345X05/form4-01102025_090146.xml…